Clinical Trials

Inclusion Criteria

• Able to understand and comply with the protocol requirements and has signed the informed consent document
• Confirmed diagnosis of B-cell Non-Hodgkin's lymphoma limited to follicular lymphoma, DLBCL, mantle cell lymphoma, marginal zone lymphoma, or CLL/SLL that has progressed and for which standard curative measures do not exist or are no longer effective
  • Prior therapy must have included a rituximab-based regimen
• DLBCL must have progressed after transplant, or unwilling, unable or not an appropriate candidate for an autologous stem cell transplant
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less
• Adequate organ and marrow function
• Able to swallow oral capsules without difficulty
• Using acceptable birth control
• Women of childbearing potential must have a negative serum or urine pregnancy test at screening

Exclusion Criteria

• Central nervous system (CNS) lymphoma is not eligible for the trial unless the disease had been treated and remains without symptoms with no active CNS lymphoma
• Not recovered from toxicity due to all prior therapies
• Other uncontrolled significant illness
• History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of apilimod
• Has undergone major surgery within 28 days prior to first dose of study drug
• Past history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C
• Is lactating and breast feeding
• Unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee
• This is a shortened list and additional criteria may apply